Drug Manufacturer Submission Deadlines

Welcome to the enhanced iDBL. The site has been enhanced with improved search features and a new look.

Important Submission Information

July 2022

The following information provides details on effective dates and deadlines for submitting Drug Product submissions to the Alberta Drug Benefit List (ADBL) for 2022 - 2023.

The following dates may be subject to change; however, you will be notified accordingly if such a change occurs.

Deadlines for Expedited Reviews of Biosimilars, Select Devices and Interchangeable Drug Products

ADBL Effective Date Deadlines for Complete Submissions
September 1, 2022 July 25, 2022
October 1, 2022 August 25, 2022
November 1, 2022 September 26, 2022
December 1, 2022 October 25, 2022
February 1, 2023 November 30, 2022
March 1, 2023 January 25, 2023
May 1, 2023 March 24, 2023
June 1, 2023 April 25, 2023
July 1, 2023 May 25, 2023
August 1, 2023 June 26, 2023
September 1, 2023 July 25, 2023
October 1, 2023 August 25, 2023

Deadlines for all other Drug Product Submission Categories

ADBL Effective Date Deadlines for Complete Submissions
September 1, 2022 June 10, 2022
November 1, 2022 August 10, 2022
February 1, 2023 October 11, 2022
March 1, 2023 December 9, 2022
May 1, 2023 February 10, 2023
July 1, 2023 April 10, 2023
September 1, 2023 June 9, 2023
November 1, 2023 August 10, 2023

Manufacturers should note that only complete submissions, satisfying all the submission requirements of the applicable category of Drug Product received by 4:30 p.m. Mountain Standard / Daylight Savings Time (as applicable) on the deadline, will be put forward for consideration by the Expert Committee on Drug Evaluation and Therapeutics or Expedited Review, as applicable. There is no guarantee that every completed submission will be reviewed and/or a recommendation made at the next scheduled meeting of the Expert Committee.

Alberta Price Confirmation Tentative Dates

The Alberta Price Confirmation (APC) is issued prior to an ADBL publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.

ADBL Effective Date APC Tentative Issue Date
February 1, 2023 December 6, 2022
March 1, 2023 February 2, 2023
May 1, 2023 March 31, 2023
June 1, 2023 May 3, 2023
July 1, 2023 June 1, 2023
August 1, 2023 July 4, 2023
September 1, 2023 August 1, 2023
October 1, 2023 September 5, 2023
November 1, 2023 October 3, 2023
December 1, 2023 November 1, 2023


Manufacturers may provide submissions for consideration for potential addition to the Alberta Drug Benefit List (ADBL) via email to the following address: submissions@ab.bluecross.ca

Submissions sent to other email addresses will not be considered for potential addition to the ADBL. It is recommended that manufacturers place the drug name(s) and strength(s) of the submitted product(s) in the subject header in order to ensure that multiple emails can be easily associated with one another.

Manufacturers are reminded that hard copies of submissions must follow by mail and should be sent to the attention of:


Scientific and Research Services

Alberta Blue Cross®

10009 – 108 Street NW

Edmonton AB T5J 3C5

A copy of covering correspondence and summary documents only should be forwarded to:

Executive Director

Pharmaceutical Funding and Guidance

Alberta Health

11th Floor, 10025 Jasper Avenue

Edmonton AB T5J 1S6

Questions or Comments

Questions or comments regarding the drug review process or submission deadlines can be addressed to:


Scientific and Research Services

Alberta Blue Cross®

10009 – 108 Street NW

Edmonton AB T5J 3C5

Phone: 780-498-8098

Fax: 780-498-3534

Email: submissions@ab.bluecross.ca


The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross® who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL (iDBL), and any such changes to the Interactive DBL (iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.